Galapagos subsidiary BioFocus and Ono sign a drug discovery agreement in the Field of CNS Disorders

04-Sep-2012 - Belgium

Galapagos NV announced that its service division BioFocus and Ono Pharmaceutical Co., Ltd. have signed a new collaboration agreement, focused on discovering novel drugs in the field of CNS disorders.  Under the new agreement, BioFocus will use its drug discovery platform to deliver leads and clinical candidates for its client.  Financial details were undisclosed.

"We are delighted to have this new agreement, which is the first drug discovery program with this, a most valued, client" said Dr. Chris Newton, SVP Galapagos Services and Managing Director of BioFocus.  "This project plays to BioFocus historic strengths and the expanding breadth and depth of this partnership is testament to a tried and trusted relationship."

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance